Physician profile
Charles Kim
NPI 1679787055
$1,850.52
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $332 · 2023: $1,096 · 2024: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $340.13 | 2022-2023 | Tepezza |
| Glaukos Corporation | $266.46 | 2022-2023 | |
| Synthes Gmbh | $250.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $164.97 | 2022 | |
| Bausch & Lomb Americas INC. | $146.67 | 2023-2024 | Miebo, Xiidra |
| Rxsight INC | $142.45 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Abbvie INC. | $139.11 | 2023 | |
| Lumenis Be INC | $128.96 | 2023 | M22 |
| Amgen INC. | $98.44 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $38.66 | 2023 | |
| Dompe US, INC. | $26.43 | 2024 | Oxervate |
| Alcon Vision LLC | $24.30 | 2023 | Simbrinza |
| Oyster Point Pharma, INC. | $23.07 | 2023 | Tyrvaya |
| Thea Pharma INC. | $22.52 | 2023 | Iyuzeh |
| Kls-Martin L.P. | $21.32 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $17.03 | 2023 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.